Amgen said there is no link between its experimental weight loss drug, MariTide, and changes in bone density. The ...
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone ...
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback